Sanam Dolati

Dr. Sanam Dolati


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
AAAli Aghebati‐Maleki
Ali Aghebati‐Maleki
SDSanam Dolati
Sanam Dolati
MAMajid Ahmadi
Majid Ahmadi
ABAmir Baghbanzhadeh
Amir Baghbanzhadeh
MAMilad Asadi
Milad Asadi
LAleili Aghebati-Maleki
leili Aghebati-Maleki

1 December 2020 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
FJFarzaneh Jafari
Farzaneh Jafari
SJSaeed Javdansirat
Saeed Javdansirat
SSSarvin Sanaie
Sarvin Sanaie
ANAmirreza Naseri
Amirreza Naseri
ASAli Shamekh
Ali Shamekh
SDSanam Dolati
Sanam Dolati

1 May 2016 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
SDSanam Dolati
Sanam Dolati
SSSanam Sadreddini
Sanam Sadreddini
Davood RostamzadehDavood Rostamzadeh
Davood Rostamzadeh
MAMajid Ahmadi
Majid Ahmadi
FJFarhad Jadidi-Niaragh
Farhad Jadidi-Niaragh
MYMehdi Yousefi
Mehdi Yousefi

2 October 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
SEShadi Eghbal‐Fard
Shadi Eghbal‐Fard
MYMehdi Yousefi
Mehdi Yousefi
HHHanieh Heydarlou
Hanieh Heydarlou
MAMajid Ahmadi
Majid Ahmadi
STSimin Taghavi
Simin Taghavi
LAleili Aghebati-Maleki
leili Aghebati-Maleki

1 January 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
RRReza Rikhtegar
Reza Rikhtegar
MPMasoud Pezeshkian
Masoud Pezeshkian
SDSanam Dolati
Sanam Dolati
NSNaser Safaie
Naser Safaie
ARAbbas Afrasiabi Rad
Abbas Afrasiabi Rad
MYMehdi Yousefi
Mehdi Yousefi
Heart Diseases are serious and global public health concern. In spite of remarkable therapeutic developments, the prediction of patients with Heart Failure (HF) is weak, and present therapeutic attitudes do not report the fundamental problem of the cardiac tissue loss. Innovative therapies are required to reduce mortality and limit or abolish the necessity for cardiac transplantation. Stem cell-based therapies applied to the treatment of heart disease is according to the understanding that natural self-renewing procedures are inherent to the myocardium, nonetheless may not be adequate to recover the infarcted heart muscle. Following the first account of cell therapy in heart diseases, examination has kept up to rapidity; besides, several animals and human clinical trials have been conducted to preserve the capacity of numerous stem cell population in advance cardiac function and decrease infarct size. The purpose of this study was to censoriously evaluate the works performed regarding the usage of four major subgroups of stem cells, including induced Pluripotent Stem Cells (iPSC), Embryonic Stem Cells (ESCs), Cardiac Stem Cells (CDC), and Skeletal Myoblasts, in heart diseases, at the preclinical and clinical studies. Moreover, it is aimed to argue the existing disagreements, unsolved problems, and prospect directions.

1 February 2019 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
SDSanam Dolati
Sanam Dolati
ZBZohreh Babaloo
Zohreh Babaloo
HAHormoz Ayromlou
Hormoz Ayromlou
MAMajid Ahmadi
Majid Ahmadi
RRReza Rikhtegar
Reza Rikhtegar
MYMehdi Yousefi
Mehdi Yousefi